⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,734.19
−1.44%
FTSE ADX
9,588.41
−1.17%
TASI
9,695.86
−2.32%
QE Index
8,611.10
−0.37%
S&P 500
7,629.51
−0.44%
Nasdaq 100
29,000.27
+0.14%
Nifty 50
22,600.00
−0.39%
Sensex
73,123.83
−0.17%
KSE-100
162,374.88
−0.95%
DFM:EMIRATESNBD
AED 30.00
−3.47%
ADX:IHC
AED 350.00
−0.57%
SAU:2222
SAR 25.40
−0.70%
DSMD:QNBK
QAR 15.50
−1.02%
NAS:NVDA
$211.89
−0.15%
NYSE:TSM
$416.80
+1.08%
NSE:RELIANCE
₹1,190.00
+0.46%
KAR:OGDC
Rs 298.12
−0.79%
Gold
$3,994.67
−0.74%
Brent
$116.33
+3.05%
BTC
$81,518.61
+0.25%
ETH
$2,404.86
+0.78%
DFM General
5,734.19
−1.44%
FTSE ADX
9,588.41
−1.17%
TASI
9,695.86
−2.32%
QE Index
8,611.10
−0.37%
S&P 500
7,629.51
−0.44%
Nasdaq 100
29,000.27
+0.14%
Nifty 50
22,600.00
−0.39%
Sensex
73,123.83
−0.17%
KSE-100
162,374.88
−0.95%
DFM:EMIRATESNBD
AED 30.00
−3.47%
ADX:IHC
AED 350.00
−0.57%
SAU:2222
SAR 25.40
−0.70%
DSMD:QNBK
QAR 15.50
−1.02%
NAS:NVDA
$211.89
−0.15%
NYSE:TSM
$416.80
+1.08%
NSE:RELIANCE
₹1,190.00
+0.46%
KAR:OGDC
Rs 298.12
−0.79%
Gold
$3,994.67
−0.74%
Brent
$116.33
+3.05%
BTC
$81,518.61
+0.25%
ETH
$2,404.86
+0.78%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Open
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Immix Biopharma Inc · News · TradingHolo
Markets
›
United States
› NAS
› IMMX
I
Immix Biopharma Inc
NAS:IMMX
Healthcare
CBOEFTSE:MRUT
NASDAQ:NQUSSG
$8.21
−1.68%
Live
In session · ≈
AED 30.15
· Market cap
$680.63M
· Next earnings
Fri 6 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
IMMX news
Headlines tagged to this company
GL
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
GlobeNewswire · 18 d ago
RE
Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
Reuters · 23 d ago
GL
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire · 23 d ago
TR
Immix Biopharma prices $125M common stock offering at $11.00 per share
TradingView · 23 d ago
QU
IMMX: Study shows 98% expected complete response and rapid organ recovery in AL amyloidosis
Quartr · 24 d ago
ST
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Stocktwits · 24 d ago
DO
Immix Biopharma Is Maintained at Buy by Needham
Dow Jones Newswires · 24 d ago
TR
Needham maintains Buy rating on Immix Biopharma, $30 price target
TradingView · 24 d ago
QU
IMMX: NXC-201 delivers rapid, deep, and durable responses with strong safety in AL amyloidosis
Quartr · 24 d ago
SE
Immix rises after new mid-stage trial data for AL amyloidosis therapy
Seeking Alpha · 24 d ago
SE
Immix Biopharma prices $125M stock offering
Seeking Alpha · 24 d ago
RE
Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Reuters · 24 d ago
GL
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
GlobeNewswire · 24 d ago
RE
Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Reuters · 24 d ago
QU
IMMX: Interim results show an 89% complete response rate in AL Amyloidosis, with potential to reach 98%
Quartr · 24 d ago
TR
Immix Biopharma interim NEXICART-2: 89% CR rate; MRD suggests up to 98% CR, BLA planned mid-2027
TradingView · 24 d ago
TR
Immix Biopharma, Inc. (IMMX) Posts 89% CR in NEXICART-2 Interim Update
TradingView · 24 d ago
PR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
PRNewsWire · 71 d ago
GL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
GlobeNewsWire · 73 d ago
PR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX
PRNewsWire · 78 d ago
More news →